Clinical trial · Observational
A Data Collection Study for Patients With Adenocarcinoma Treated With the MyVaccx Immunotherapy Regimen.
A Retrospective and Prospective Study of a New Immunotherapy Regimen (MyVaccx) for Patients With Adenocarcinoma.
NCT03695835CI-TRIAL-00046094NIRPAcompletedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
A retrospective and prospective data collection study on 27 consecutive subjects with adenocarcinoma who were treated using the MyVaccx system by Dr. Gary Onik. Retrospective data were collected on the treatment with the immunotherapy system and prospective data will be collected as they are prospectively monitored through their normal standard of care for their original cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Adenocarcinoma | Adenocarcinoma | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Ablation | Device | — | UNRESOLVED |
| Immunotherapeutic Agents | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Adenocarcinoma treated with MyVaccx
- description
- MyVaccx combines tumor ablation and immunotherapeutic agents for treatment of late stage cancer disease..
- interventionNames
- Drug: Immunotherapeutic Agents
- Device: Ablation
Primary outcomes (1)
- measure
- MyVaccx immunotherapy treatment impact on late stage cancer disease
- timeFrame
- From date of treatment until the date of death from any cause up to 60 months
- description
- Time to death after the start of treatment
Secondary outcomes (1)
- measure
- MyVaccx immunotherapy treatment impact on late stage cancer disease
- timeFrame
- Time to progression after a complete or partial response up to 60 months
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 19 Years
Show eligibility criteria text
Inclusion Criteria: * Treatment with the MyVaccx System * Greater than 18 years of age * Signature of the informed consent Exclusion Criteria: * 2 subjects treated with the MyVaccx System with known visceral disease
References
Publications (0)
Data not yet available
No reference posted for this study.